NICE recommends epcoritamab for DLBCL

The National Institute for Health and Care Excellence (NICE) has recommended epcoritamab as an option for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults after 2 or more systemic (whole body) therapies. Epcoritamab is available as a treatment option only if previously treated with polatuzumab vedotin, or if polatuzumab vedotin is not suitable.

Epcoritamab is a bispecific antibody, which is a new class of immunotherapy drug. Bispecific antibodies work by attaching to two targets, one on the surface of lymphoma cells and one on the surface of T cells (part of the immune system). This means that cells of the immune system come into direct contact with the lymphoma cells, and this leads to activation of the T-cells which in turn kill the lymphoma cells.  

Find out more about drug development, approval and funding, or visit Lymphoma TrialsLink for the latest on clinical trials for lymphoma.